Skip to main content

Understanding the Benefits and Risks of Pharmaceuticals Workshop Summary (2007) / Chapter Skim
Currently Skimming:

Appendix A Workshop Agenda
Pages 63-68

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 63...
... Food and Drug Administration Jeffrey Leiden, M.D., Ph.D. President and COO, Abbott Laboratories 
Read the entire page →
From page 64...
... President, Decision Research Peter Ubel, M.D. Director, Center for Behaioral and Decision Sciences in Medicine, Uniersity of Michigan Sheila Jasanoff, J.D., Ph.D.
Read the entire page →
From page 65...
... Food and Drug Administration Brian Strom, M.D., M.P.H. Chair, Department of Biostatistics and Epidemiology, Uniersity of Pennsylania 3:05 pm Discussion 3:30 pm Break 3:45 pm Advantages and drawbacks of the current system Discussion Leaders: Tim Franson, M.D., and Sandra Kweder, M.D.
Read the entire page →
From page 66...
... Senior Vice President and Director, The Boston Consulting Group David Slavin, M.D. Executie Director, World Wide Deelopment Business Innoations Unit, Pfizer Inc.
Read the entire page →
From page 67...
... Professor, Enironmental Health Sciences, Johns Hopkins Uniersity John Graham, Ph.D. Former Administrator, Office of Management and Budget, Office of Information and Regulatory Affairs 10:30 am Discussion 11:00 am Break 11:15 am What specific methodologies from other industries or academia are adaptable to the drug review system?
Read the entire page →
From page 68...
... Food and Drug Administration 3:00 pm Discuss how new approaches could work with the case example (Zometa) (15 minute presentations)
Read the entire page →

Key Terms

  • steven galson
  • industries discussion
  • minute presentations
  • sandra kweder
  • drug review

  • family medicine
  • brian strom
  • information exchange
  • boston consulting
  • burling llp

  • peter barton
  • pharmaceuticals discussion
  • former administrator
  • associate research
  • tim franson

  • senior counsel
  • health information
  • pfizer inc
  • mark berger
  • regulatory affairs

  • indiana health
  • unique challenges
  • research professor
  • assessment discussion
  • regenstrief institute

  • specific methodologies
  • england medical
  • barton hutt
  • paul seligman
  • drug administration


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.